Business Context and Reporting Period
This Form 8-K was filed by Integrity Applications, Inc. (not Glucotrack, Inc.) on May 3, 2017, reporting events occurring on April 28, 2017. The company, incorporated in Delaware with principal offices in Ashdod, Israel, announced the tenth closing of a securities offering.
Key Financial Metrics and Transaction Details
- Gross Proceeds: $1,551,000 received from the sale of 1,551 Units.
- Instrument Structure: Each Unit consists of one share of Series C 5.5% Convertible Preferred Stock and two five-year warrants (Series C-1 and Series C-2).
- Conversion Terms: Preferred Stock converts to Common Stock at $4.50 per share. The 1,551 Units are convertible into an aggregate of 344,682 shares of Common Stock.
- Warrant Terms:
- Series C-1 Warrants: Exercise price of $4.50 per share.
- Series C-2 Warrants: Exercise price of $7.75 per share.
- Total Warrant Coverage: Exercisable for an aggregate of 689,364 shares of Common Stock.
- Placement Agent Compensation:
- Cash Commission: 10% of aggregate sales price ($155,100).
- Expense Allowance: 3% of aggregate sales price ($46,530).
- Warrants Issued to Agent: 68,934 shares at $4.50 and 34,467 shares at $7.75, including full ratchet anti-dilution protection.
Note: This filing does not provide data on revenue, operating profit, cash flow, margins, or total debt levels.
Material Changes and Prior Activity
This transaction represents the tenth closing of an ongoing offering. The terms of the Preferred Stock and Warrants are identical to those issued in nine prior closings between April 2016 and March 2017. The prior closings involved the sale of an aggregate of 8,792.9 Units. No material changes to the capital structure terms were introduced in this specific closing compared to the prior issuances.
Outlook, Risks, and Contingencies
The filing does not contain management commentary on future outlook, specific risks, or contingencies beyond the standard terms of the securities issued. The sale was conducted without registration under the Securities Act of 1933, relying on the Section 4(a)(2) exemption for accredited investors. The issuance of warrants with full ratchet anti-dilution protection to the placement agent represents a potential dilution contingency for existing shareholders.
Investor Verification Checklist
- Verify the total number of Units issued across all ten closings to assess total dilution impact.
- Confirm the current cash position of the company to determine runway following the $1.55 million raise.
- Review the "Prior 8-Ks" referenced in the filing to understand the full scope of the offering and any changes in investor composition.
- Assess the impact of the placement agent's full ratchet anti-dilution warrants on future share price and conversion value.
- Clarify the discrepancy between the requested company name (Glucotrack, Inc.) and the filing registrant (Integrity Applications, Inc.).